Because ACLY is usually over-expressed in a variety of cancers, changing the citric acid binding site of the enzyme, indirect transcyclic citric acid-binding is one of the cancer treatment options, an ACLY inhibitor, such as SB-204990, produces a strong inhibitory effect on lung cancer, prostate cancer, and other mouse tumors [35]. Here, ACLY is linked to lung cancer.